Abstract
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are distinct but related aspects of the same dynamic disease process known as venous thromboembolism (VTE). An estimated 200,000 new cases occur in the United States every year, including 94,000 with PE, resulting in an incidence of 23 per 100,000 patients per year-cases. Without treatment, pulmonary embolism is associated with a mortality rate of approximately 30%, causing nearly 50,000 deaths per year. Moreover, based on post-mortem studies, two-thirds of the patients with pulmonary emboli remain undiagnosed. Clinically, PE may present as (1) isolated dyspnea, (2) pleuritic pain and/or hemoptysis, and (3) circulatory collapse. However, clinical history and examination can be notoriously misleading in reaching a diagnosis. A number of acquired etiologic risk factors (predispositions) are associated with a tendency to develop VTE. These include increasing age, immobilization, surgery, trauma, hospital or nursing home confinement, malignancy, neurologic disease with extremity paresis, as well as certain types of oral contraception and hormone replacement therapy. In addition, a variety of genetic risk factors, such as factor V Leiden, protein S or C deficiency have also been identified. However, in at least half of the instances, no predisposing factors can be identified (idiopathic PE). In the majority of cases thromboemboli originate in the deep veins of the calf or pelvis. The pathogenic conditions for VTE comprise a triad of factors and include (1) venous stasis, (2) hypercoagulable states, and (3) vascular endothelium injury. Occlusion of pulmonary arteries has variable and transient clinical and pathophysiologic consequences, involving both mechanical and reflex effects of vascular occlusion with a consecutive perfusion defect as well as the release of vasoactive and other inflammatory mediators. The objectives of this article are to present an overview of the etiologic and pathogenic factors promoting VTE as well as the pathophysiologic and inflammatory processes following PE.
References
1.
Goldhaber SZ: Pulmonary embolism. N Engl J Med 1998;339:93–104.
2.
Siddique RM, Siddique MI, Rimm AA: Trends in pulmonary embolism mortality in the US elderly population: 1984 through 1991. Am J Public Health 1998;88:478–480.
3.
D’Angelo E: Advance in basic laboratory and clinical aspects of thromboembolic diseases: Lung mechanics and gas exchange in pulmonary embolism. Haematologica 1997;82:371–374.
4.
Perrier A: Noninvasive diagnosis of pulmonary embolism. Haematologica 1997;82:328–331.
5.
Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933–938.
6.
Dalen JE, Alpert JS: Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975;17:257–270.
7.
Clagett GP, Anderson FA Jr, Heit J, et al: Prevention of venous thromboembolism. Chest 1995;108(suppl):312S–334S.
8.
Garg K: CT of pulmonary thromboembolic disease. Radiol Clin North Am 2002;40:111–122.
9.
Gray HW: The natural history of venous thromboembolism: Impact on ventilation/perfusion scan reporting. Semin Nucl Med 2002;32:159–172.
10.
Atrash HK, Koonin LM, Lawson HW, Franks AL, Smith JC: Maternal mortality in the United States, 1979–1986. Obstet Gynecol 1990;76:1055–1060.
11.
Dalen JE: Pulmonary embolism: What have we learned since Virchow?: Treatment and prevention. Chest 2002;122:1801–1817.
12.
Heit JA: Venous thromboembolism epidemiology: Implications for prevention and management. Semin Thromb Hemost 2002;28(suppl 2):3–14.
13.
Nordstrom M, Lindblad B: Autopsy-verified venous thromboembolism within a defined urban population: The city of Malmö, Sweden. APMIS 1998;106:378–384.
14.
Coon WW, Coller FA: Clinicopathologic correlation in thromboembolism. Surg Gynecol Obstet 1959;109:259–269.
15.
Morrell MT, Dunnill MS: The post-mortem incidence of pulmonary embolism in a hospital population. Br J Surg 1968;55:347–352.
16.
Goldhaber SZ, Hennekens CH, Evans DA, Newton EC, Godleski JJ: Factors associated with correct ante-mortem diagnosis of major pulmonary embolism. Am J Med 1982;73:822–826.
17.
Stein PD, Henry JW: Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995;108:978–981.
18.
The Columbus Investigators: Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657–662.
19.
Simonneau G, Sors H, Charbonnier B, et al: A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism: The THESEE Study Group; Tinzaparine ou Héparine Standard – Evaluations dans l’Embolie Pulmonaire. N Engl J Med 1997;337:663–669.
20.
Goldhaber SZ, Visani L, De Rosa M: Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386–1389.
21.
Kasper W, Konstantinides S, Geibel A, et al: Management strategies and determinants of outcome in acute major pulmonary embolism: Results of a multicenter registry. J Am Coll Cardiol 1997;30:1165–1171.
22.
Secker-Walker RH, Jackson JA, Goodwin J: Resolution of pulmonary embolism. Br Med J 1970;4:135–141.
23.
Winebright JW, Gerdes AJ, Nelp WB: Restoration of blood flow after pulmonary embolism. Arch Intern Med 1970;125:241–247.
24.
Austin JHW, Wilner GD, Dominguez C: Natural history of pulmonary thromboemboli in dogs: Serial radiographic observations of clots labeled with powdered tantalum. Radiology 1975;116:519–527.
25.
Moser KM, Guisan M, Bartimmo EE, Longo AM, Harsanyi PG, Chiorazzi N: In vivo and post mortem dissolution rates of pulmonary emboli and venous thrombi in the dog. Circulation 1973;48:170–178.
26.
Moser KM, LeMoine JR: Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med 1981;94:439–444.
27.
Miller GA, Sutton GC: Acute massive pulmonary embolism: Clinical and haemodynamic findings in 23 patients studied by cardiac catheterization and pulmonary arteriography. Br Heart J 1970;32:518–523.
28.
Gorham LW: A study of pulmonary embolism: To the mechanism of death based on a clinical pathological investigation of 100 cases of massive and 285 cases of minor embolism of the pulmonary artery. Arch Intern Med 1961;108:76–90.
29.
Del Guercio LRM, Cohn JDFNR: Pulmonary embolism shock: Physiologic basis of a bedside screening test. JAMA 1960;196:751–756.
30.
McDonald IG, Hirsh J, Hale GS, et al: Major pulmonary embolism, a correlation of clinical findings, haemodynamics, pulmonary angiography, and pathological physiology. Br Heart J 1972;34:356–364.
31.
Alderson PO, Dzebolo NN, Biello DR, et al: Serial lung scintigraphy: Utility in diagnosis of pulmonary embolism. Radiology 1983;149:797–804.
32.
Tow DE, Wagner NH Jr: Recovery of pulmonary arterial blood flow in patients with pulmonary embolism. N Engl J Med 1967;276:1053–1059.
33.
Hampton AO, Castleman B: Correlation of postmortem chest teleroentgenograms with autopsy findings. Am J Roentgenol Radium Ther 1940;43:305–326.
34.
Simon M: Plain film and angiographic aspect of pulmonary embolism; in Moser K, Stein M (eds): Pulmonary Thromboembolism. Chicago, Yearbook Medical Publishers, 1973.
35.
Urokinase Pulmonary Embolism Trial (UPET): Phase 1 results: A cooperative study. JAMA 1970;214:2163–2172.
36.
Hoagland PM: Massive pulmonary embolism: Pulmonary embolism and deep vein thrombosis. Philadelphia, Saunders, 1985, pp 179–208.
37.
Morgenthaler T, Ryu J: Clinical characteristics of fatal pulmonary embolism in a referral hospital. Mayo Clin Proc 1995;70:417–424.
38.
Morpurgo M, Rustici A: The clinical picture of pulmonary embolism. Cardiologia 1988;33:1105–1108.
39.
Morpurgo M, Schmid C: The spectrum of pulmonary embolism. Clinicopathologic correlations. Chest 1995;107(suppl):18S–20S.
40.
Alpert JS, Smith R, Carlson J, et al: Mortality in patients treated for pulmonary embolism. JAMA 1976;236:1477–1480.
41.
McIntyre KM, Sasahara AA: The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. Am J Cardiol 1971;28:288–294.
42.
McIntyre KM, Sasahara AA: Hemodynamic and ventricular responses to pulmonary embolism. Prog Cardiovasc Dis 1974A;17:175–190.
43.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O’Fallon WM, Melton LJ 3rd: The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001;86:452–463.
44.
Carson JL, Kelley MA, Duff A, et al: The clinical course of pulmonary embolism: One-year follow-up of PIOPED patients. N Engl J Med 1992;326:1240–1245.
45.
Moser KM: Venous thromboembolism. Am Rev Respir Dis 1990;141:235–249.
46.
Tapson VF, Witty LA: Massive pulmonary embolism. Diagnostic and therapeutic strategies. Clin Chest Med 1995;16:329–340.
47.
Towbin A: Pulmonary embolism: Incidence and significance. JAMA 1954;156:209–215.
48.
Pineda LA, Hathwar VS, Grant BJB: Clinical suspicion of fatal pulmonary embolism. Chest 2001;120:791–795.
49.
Trousseau A: Phlegmasia alba colens. Clinique Médicale de l`Hôtel-Dieu de Paris, the New Sydennam Society, London 1865;3:94–111.
50.
Sorensen HT, Mellemkjaer L, Steffensen FH, et al: The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998;338:1169–1173.
51.
Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846–1850.
52.
Bauer KA: Venous thromboembolism in malignancy. J Clin Oncol 2000;18:3065.
53.
Prandoni P, Lensing AWA, Buller HR, et al: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128–1133.
54.
Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, Sandmann W, Zotz RB: Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000;342:374–380.
55.
Virchow RLK: Gesammelte Abhandlungen zur wissenschaftlichen Medizin. Frankfurt, Meidinger, 1856, pp 285–294–296.
56.
White RH, Romano PS, Zhou H, et al: Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525–1531.
57.
Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G: Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696–700.
58.
Kistner RL, Ball JJ, Nordyke RA, Freeman GC: Incidence of pulmonary embolism in the course of thrombophlebitis of the lower extremities. Am J Surg 1972;124:169–176.
59.
Weinmann EE, Salzman EW: Deep-vein thrombosis. N Engl J Med 1994;331:1630–1641.
60.
Furie B, Furie BC: Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800–806.
61.
Neumann FJ, Ott I, Marx N, et al: Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997;17:3399–3405.
62.
van den Eijnden MM, Steenhauer SI, Reitsma PH, et al: Tissue factor expression during monocyte-macrophage differentiation. Thromb Haemost 1997;77:1129–1136.
63.
Yamamoto M, Nakagaki T, Kisiel W: Tissue factor-dependent autoactivation of human blood coagulation factor. J Biol Chem 1992;267:19089–19094.
64.
Gailani D, Broze GJ Jr: Factor XI activation by thrombin and factor XIa. Semin Thromb Hemost 1993;19:396–404.
65.
Thompson CA, Skelton TN: Thromboembolism in the right side of the heart. South Med J 1999;92:826–830.
66.
Casazza F, Bongarzoni A, Centonze F, et al: Prevalence and prognostic significance of right-sided cardiac mobile thrombi in acute massive pulmonary embolism. Am J Cardiol 1997;79:1433–1435.
67.
Chernick V, Hodson WH, Greenfield LJ: Effects of chronic pulmonary artery ligation on pulmonary mechanisms and surfactant. J Appl Physiol 1966;21:1315–1320.
68.
Kronik G: The European Cooperative Study on the clinical significance of right heart thrombi: European Working Group on Echocardiography. Eur Heart J 1989;10:1046–1059.
69.
Wittlich N, Erbel R, Eichler A, et al: Detection of central pulmonary thromboemboli by transesophageal echocardiography in patients with severe pulmonary embolism. J Am Soc Echocardiogr 1992;5:515–524.
70.
Farfel Z, Shechter M, Vered Z, et al: Review of echocardiographically diagnosed right heart entrapment of pulmonary emboli-in-transit with emphasis on management. Am Heart J 1987;113:171–178.
71.
Krivec, B, Voga, G, Zuran, I, et al: Diagnosis and treatment of shock due to massive pulmonary embolism. Chest 1997;112:1310–1316.
72.
Morgenstern E, Korell U, Richter J: Platelets and fibrin strands during clot retraction. Thromb Res 1984;33:617–623.
73.
Sabovic M, Lijnen HR, Keber D, et al: Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis. Thromb Haemost 1990;64:450–454.
74.
Lin PH, Chen C, Sourowiec SM, et al: Evaluation of thrombolysis in a porcine model of chronic deep venous thrombosis: An endovascular model. J Vasc Surg 2001;33:621–627.
75.
O’Shaughnessy AM, Fitzgerald DE: Determining the stage of organisation and natural history of thrombosis using computer analysis. Int Angiol 2000;19:220–227.
76.
Chan RK, Johns JA, Calafiore P: Clinical implications of the morphological features of central pulmonary artery thromboemboli shown by transoesophageal echocardiography. Br Heart J 1994;72:58–62.
77.
Karsner HT, Ash JE: Studies in infarctions. I. Experimental bland infarction of the lung. J Med Res 1912/1913;27:205–211.
78.
Chapman DW, Gugle LJ, Wheeler PW: Experimental pulmonary infarction: Abnormal pulmonary circulation is a prerequisite for pulmonary infarction following an embolus. Arch Intern Med 1949;83:158–163.
79.
Dalen JE, Haffajee CI, Alpert JS, et al: Pulmonary embolism, pulmonary hemorrhage and pulmonary infarction. N Engl J Med 1977;296:1431–14340.
80.
Clark SW, Graf PD, Madel JA: In vivo visualisation of small airway constriction after pulmonary microembolism in cats and dogs. J Appl Physiol 1970;29:646–650.
81.
Nadel JA, Colebatch HJH, Olsen CR: Location and mechanism of airway constriction after sulfate microembolism. J Appl Physiol 1964;19:387–394.
82.
Lindquist O, Saldeen T, Sandler H: Pulmonary damage following pulmonary microembolism in the dog. Effect of various types of treatment. Acta Chir Scand 1976;142:15–19.
83.
Nakos, G, Kitsiouli, EI, Lekka, ME: Bronchoalveolar lavage alterations in pulmonary embolism. Am J Respir Crit Care Med 1998;158:1504–1510.
84.
Reeves WC, Demers LM, Wood MA, Skarlatos S, Copenhaver G, Whitesell L, Luderer JR: The release of thromboxane A2 and prostacyclin following experimental acute pulmonary embolism. Prostaglandins Leukot Med 1983;11:1–10.
85.
Frazer RG, Paré JAP, Paré PD, Frazer RS, Genereux GP: Embolic and thrombotic diseases of the lung; in Frazer RG, Paré JAP, Paré PD, Frazer RS, Genereux GP (eds): Diagnosis of diseases of the chest, ed 3. Philadelphia, Saunders, 1990, pp 1701–1813.
86.
Remy-Jardin M, Remy J, Deschildre F, et al: Diagnosis of pulmonary embolism with spiral CT: Comparison with pulmonary angiography and scintigraphy. Radiology 1996;200:699–706.
87.
Stern EJ, Müller NL, Swensen SJ, Hartman TE: CT mosaic pattern of lung attenuation: Etiologies and terminology. J Thorac Imaging 1995;10:294–297.
88.
Malik AB, Van der Zee H: Mechanism of pulmonary edema induced by microembolization in dogs. Circ Res 1978;42:72–79.
89.
Ohkuda K, Nakahara K, Weidner WJ: Lung fluid exchange after uneven pulmonary artery obstruction in sheeps. Circ Res 1978;43:152–161.
90.
Bergin CJ, Rios G, King MA, Belezzuoli E, Luna J, Auger WR: Accuracy of high-resolution CT in identifying chronic pulmonary thromboembolic disease. AJR 1996;166:1371–1377.
91.
Roberts HC, Kauczor HU, Schweden F, Thelen M: Spiral CT of pulmonary hypertension and chronic thrombembolism. J Thorac Imaging 1997;12:118–127.
92.
Schwickert HC, Schweden F, Schild HH, Piepenburg R, Duber C, Kauczor HU, Renner C, Iversen S, Thelen M: Pulmonary arteries and lung parenchyma in chronic pulmonary embolism: Preoperative and postoperative CT findings. Radiology 1994;191:351–357.
93.
King MA, Bergin CJ, Yeung DWC, et al: Chronic pulmonary thromboembolism: Detection of regional hypoperfusion with CT. Radiology 1994;191:359–363.
94.
Primack SL, Müller NL, Mayo JR, Remy-Jardin M, Remy J: Pulmonary parenchymal abnormalities of vascular origin: High-resolution CT findings. RadioGraphics 1994;14:739–746.
95.
Levinson RM, Shure D, Moser KM: Reperfusion pulmonary edema after pulmonary artery thromboendarterectomy. Am Rev Respir Dis 1986;134:1241–1245.
96.
Miller WT Jr, Osiason AW, Langlotz CP, Palevsky HI: Reperfusion pulmonary edema after thromboendarterectomy: Radiographic patterns of disease. J Thorac Imaging 1998;13:178–183.
97.
Moser KM, Daily PO, Peterson K, et al: Thromboendarterectomy for chronic, major-vessel thromboembolic pulmonary hypertension: Immediate and long-term results in 42 patients. Ann Intern Med 1987;107:560–565.
98.
Kerr IH, Simon G, Sutton GC: The value of the plain radiograph in acute massive embolism. Br J Radiol 1971;44:751–756.
99.
Elliott CG, Goldhaber SZ, Visani L, DeRosa M: Chest radiographs in acute pulmonary embolism. Results from the International Cooperative Pulmonary Embolism Registry. Chest 2000;118:33–38.
100.
Levy SE, Simmons DH: Mechanism of arterial hypoxemia following pulmonary thromboembolism in dogs. J Appl Physiol 1975;39:41–46.
101.
Wood KE: Major Pulmonary Embolism. Review of a Pathophysiologic Approach to the Golden Hour of Hemodynamically Significant Pulmonary Embolism Chest 2002;121:877–905.
102.
D’Alonzo GE, Dantzker DR: Gas exchange alterations following pulmonary thromboembolism. Clin Chest Med 1986;5:411–419.
103.
Caldini P: Pulmonary hemodynamics and arterial oxygen saturation in pulmonary embolism. J Appl Physiol 1965;20:184–190.
104.
Manier GY, Castaing Y, Guenard GH: Determinants of hypoxemia during acute phase of pulmonary embolism in humans. Am Rev Respir Dis 1985;132:332–338.
105.
Dantkzer DR, Wagner PD, Tornabene VW, et al: Gas exchange after pulmonary thromboembolization in dogs. Circ Res 1978;42:92–103.
106.
Wilson JE, Pierce AK, Johnson RL: Hypoxemia in pulmonary embolism: A clinical study. J Clin Invest 1971;50:481–491.
107.
Moorthy SS, Losasso AM, Gibbs PS: Acquired right to left intracardiac shunt in severe hypoxemia. Crit Care Med 1978;6:28–31.
108.
Jardin F, Gurdjian F, Desfonds P, et al: Hemodynamic factors influencing arterial hypoxemia in massive pulmonary embolism with circulatory failure. Circulation 1979;59:909–912.
109.
Jehle R, Schlame M, Buttner C, Frey B, Sinha P, Rustow B: Platelet-activating factor (PAF)-acetylhydrolase and PAF-like compounds in the lung: Effects of hyperoxia. Biochim Biophys Acta 2001;1532:60–66.
110.
Dantzker DR, Bower JS: Alterations in gas exchange following pulmonary thromboembolism. Chest 1982;81:495–501.
111.
Masotti L, Ceccarelli E, Cappelli R, Barabesi L, Forconi S: Arterial blood gas analysis and alveolar-arterial oxygen gradient in diagnosis and prognosis of elderly patients with suspected pulmonary embolism. J Gerontol A Biol Sci Med Sci 2000;55:M761–M764.
112.
Benotti JR, Dalen JE: The natural history of pulmonary embolism. Clin Chest Med 1984;5:403–410.
113.
Stein M, Levy SE: Reflex and humoral responses to pulmonary embolism. Prog Cardiovasc Dis 1974;17:167–174.
114.
Malik AB. Pulmonary microembolism. Physiol Rev 1983;63:1114–1207.
115.
Alpert JS, Godtfredsen J, Ockene IS, et al: Pulmonary hypertension secondary to minor pulmonary embolism. Chest 1978;73:795–797.
116.
Miller GA, Hall RJ, Paneth M: Pulmonary embolectomy, heparin, and streptokinase: Their place in the treatment of acute massive pulmonary embolism. Am Heart J 1977;93:568–574.
117.
Diehl JL, Meyer G, Igual J, et al: Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. Am J Cardiol 1992;70:1477–1480.
118.
Meneveau N, Schiele F, Metz D, et al: Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: Immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 1998;31:1057–1063.
119.
Bynum LJ, Wilson JE 3rd: Radiographic features of pleural effusions in pulmonary embolism. Am Rev Respir Dis 1978;117:829–834.
120.
Reissig A, Heyne JP, Kroegel C: Sonography of lung and pleura in pulmonary embolism: Sonomorphologic characterization and comparison with spiral CT scanning. Chest 2001;120:1977–1983.
121.
Bynum LJ, Wilson JE: Characteristics of pleural effusions associated with pulmonary embolism. Arch Intern Med 1976;136:159–162.
122.
Light RW: Pleural effusion due to pulmonary emboli. Curr Opin Pulm Med 2001;7:198–201.
123.
Cheng D, Rodriguez RM, Perkett EA, Rogers J, Bienvenu G, Lappalainen U, Light RW: Vascular endothelial growth factor in pleural fluid. Chest 1999;116:760–765.
124.
Light RW: Pleural effusion due to pulmonary embolization. Pleural diseases, ed 3. Baltimore, Williams & Wilkins, 1995, pp 187–191.
125.
Adelman M, Albelda SM, Gottlieb J, et al: Diagnostic utility of pleural fluid eosinophilia. Am J Med 1984;77:915–920.
126.
Downing LJ, Strieter RM, Kadell AM, Austin JC, Hare BD, Burdick MD, Greenfield LJ, Wakefield TW: IL-10 regulates thrombus-induced vein wall inflammation and thrombosis. J Immunol 1998;161:1471–1476.
127.
Wakefield TW, Strieter RM, Wilke CA, Kadell AM, Wrobleski SK, Burdick MD, Schmidt R, Kunkel SL, Greenfield LJ: Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arterioscler Thromb Vasc Biol 1995;15:258–268.
128.
Tan P, Luscinskas FW, Homer-Vanniasinkam S: Cellular and molecular mechanisms of inflammation and thrombosis. Eur J Vasc Endovasc Surg 1999;17:373–389.
129.
Granger DN, Kubes P: The microcirculation and inflammation: Modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994;55:662–675.
130.
Kaplanski G, Marin V, Fabrigoule M, Boulay V, Benoliel A, Bongrano P, Kaplanski S, Farnarier C: Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood 1998;92:1259–1267.
131.
Sugama Y, Tiruppathi C, Janakidevi K, Andersen TT, Fenton JW, Malik AB: Thrombin-induced expression of endothelial p-selectin and intercellular adhesion molecule-1: A mechanism for stabilizing neutrophil adhesion. J Cell Biol 1992;119:935–944.
132.
Wakefield TW, Strieter RM, Schaub R, Myers DD, Prince MR, Wrobleski SK, Londy FJ, Kadell AM, Brown SL, Henke PK, Greenfield LJ: Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy. J Vasc Surg 2000;31:309–324.
133.
Cooper JA, Solano SJ, Bizios R, Kaplan JE, Malik AB: Pulmonary neutrophil kinetics after thrombin-induced intravascular coagulation. J Appl Physiol 1984;57:826–832.
134.
Perlman MB, Johnson A, Jubiz W, Malik AB: Lipoxygenase products induce neutrophil activation and increase endothelial permeability after thrombin-induced pulmonary microembolism. Circ Res 1989;64:62–73.
135.
Stewart G, Ritchie WG, Lynch PR: Venous endothelial damage produced by massive sticking and emigration of leukocytes. Am J Pathol 1974;74:507–532.
136.
Eagleton MJ, Henke PK, Luke CE, Hawley AE, Bedi A, Knipp BS, Wakefield TW, Greenfield LJ: Inflammation and intimal hyperplasia associated with experimental pulmonary embolism. J Vasc Surg 2002;36:581–588.
137.
Van Golde LMG, Batenburg JJ, Robertson B: The pulmonary surfactant system. Physiol Rev 1988;68:374–455.
138.
Nakos G, Pneumatikos J, Tsangaris H, Telis K, Lekka ME: Protein and phospholipids in BAL from patients with hydrostatic pulmonary edema. Am J Respir Crit Care Med 1997;155:945–951.
139.
Hida W, Hildebrandt J: Alveolar surface tension, lung inflation, and hydration effect on interstitial pressure [Px(f)]. J Appl Physiol 1984;57:262–270.
140.
Mazzone PJ, Thomassen MJ, Kavuru MS: Pulmonary alveolar proteinosis. Semin Respir Crit Care Med 2002;23:115–126.
141.
Wright JR, Dodds LG: Regulation of pulmonary surfactant secretion and clearance. Annu Rev Physiol 1991;53:395–414.
142.
Oyarzun MJ, Clements JA: Control of lung surfactant by ventilation, adrenergic mediators and prostaglandins in the rabbit. Am Rev Respir Dis 1978;117:879–891.
143.
Kikkawa Y, Smith F: Cellular and biochemical aspects of pulmonary surfactant in health and disease. Lab Invest 1983;49:122–139.
144.
Fukahori, M, Murata T, Mohammed MU, Fukuyama N, Nakazawa H: Early reperfusion induces alveolar injury in pulmonary embolism. Chest 1997;111:198–203.
145.
Cirino G, Cicala C, Bucci MR, Sorrentino L, Maraganore JM, Stone SR: Thrombin functions as an inflammatory mediator through activation of its receptor. J Exp Med 1996;183:821–827.
146.
Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA: Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cell. J Exp Med 1984;160:618–623.
147.
Toosi Z, Sedor JR, Mettler MA, Everson B, Young T, Ratnoff OD: Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII). Proc Natl Acad Sci USA 1992;89:11969–11972.
148.
Kroegel C: The potential pathophysiological role of the platelet-activating factor (PAF) in human disease. Klin Wschr 1988;66:373–378.
149.
Lorant DE, Patel KDA, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA: Coexpression of GMP-140 and platelet activating factor by endothelium stimulated by histamine and thrombin: A juxtacrine system for adhesion and activation of neurophils. J Cell Biol 1991;115:223–234.
150.
Kroegel C, Kortsik C, Kroegel N, Matthys H: The pathophysiological role and therapeutic implications of platelet activating factor in disease of aging. Drugs Aging 1992;2:345–355.
151.
Kaplanski G, Fabrigoule M, Boulay V, Dinarello CA, Bongrand P, Farnarier C: Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-independent IL-8 secretion and E-selectin expression. J Immunol 1997;158:5435–5441.
152.
Colotta F, Sciacca FL, Sironi M, Luini W, Rabiet MJ, Mantovani A: Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 1994;144:975–985.
153.
Hanahan DJ: Platelet-activating factor: A biologically active phosphoglyceride. Annu Rev Biochem 1986;55:483–509.
154.
Smith CS, Parker L, Shearer WT: Cytokine regulation by platelet-activating factor in a human B cell line. J Immunol 1994;153:3997–4005.
155.
Voelkel NF, Stenmark KR, Reeves JT, Mathias MM, Murphy RC: Nonimmunologic production of leukotrienes induced by platelet-activating factor. Science 1982;218:286–288.
156.
Lekka ML, Tokumura A, Tsuji H, Hanahan DJ: Isolation of a phospholipid inhibitor of platelet activating factor-induced activity from perfused rat liver: Identification as phosphatidylglycerol. Arch Biochem Biophys 1993;302:380–384.
157.
Kroegel C, Foerster M, Häfner D, Grahmann R, Warner JA, Braun R: Putting priming in perspective – From cellular heterogeneity to cellular plasticity. Immunol Today 2000;21:218–222.
158.
Tamaoki J, Kondo M, Nakata J, Nagano Y, Isono K, Nagai A: Effect of a thromboxane A antagonist on sputum production and its physicochemical properties in patients with mild to moderate asthma. Chest 2000;118:73–79.
159.
Waltham M, Burnand KG, Collins M, Smith A: Vascular endothelial growth factor and basic fibroblast growth factor are found in resolving venous thrombi. J Vasc Surg 2000;32:988–996.
160.
Maloney JP, Silliman CC, Ambruso DR, et al: In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 1998;275:H1054–H1061.
161.
Wartiovaara U, Salven P, Mikkola H, et al: Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998;80:171–175.
162.
Henke PK, Wakefield TW, Kadell AM, Linn MJ, Varma MR, Sarkar M, Hawley A, Fowlkes JB, Strieter RM: Interleukin-8 administration enhances venous thrombosis resolution in a rat model. J Surg Res 2001;99:84–91.
163.
Downing LJ, Wakefield TW, Strieter RM, Prince MR, Londy FJ, Fowlkes JB, Hulin MS, Kadell AM, Wilke CA, Brown SL, et al: Anti-p-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J Vasc Surg 1997;25:816–827.
164.
Myers DD Jr, Schaub R, Wrobleski SK, Londy FJ 3rd, Fex BA, Chapman AM, Greenfield LJ, Wakefield TW: P-selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb Haemost 2001;85:423–429.
165.
Eppihimer MJ, Schaub RG: P-Selectin-dependent inhibition of thrombosis during venous stasis. Arterioscler Thromb Vasc Biol 2000;20:2483–2488.
166.
PIOPED Investigators: Value of the ventilation/perfusion scan in acute pulmonary embolism: Results of the prospective investigation of pulmonary embolism (PIOPED). JAMA 1990;263:2753–2759.
167.
Cheriex EC, Sreeram N, Eussen YF, et al: Cross-sectional Doppler echocardiography as the initial technique for diagnosis of acute pulmonary embolism. Br Heart J 1994;72:52–57.
168.
Podbregar M, Krivec B, Voga G: Impact of morphologic characteristics of central pulmonary thromboemboli in massive pulmonary embolism. Chest 2002;122:973–979.
169.
Corris P, Ellis D, Foley N, et al for the Standards of Care Committee of the British Thoracic Society: Suspected acute pulmonary embolism: A practical approach. Thorax 1997;52(suppl 4):S1–S24.
170.
Stein PD, Henry JW: Clinical characteristics of patients with acute pulmonary embolism stratified according to their presenting syndromes. Chest 1997;112:974–979.
171.
Cuss FM, Dixon CMS, Barnes PJ: Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet 1986;2:189–192.
172.
Taheri SA, Shenoy S, Murawski S, Divan K, Cullin J, Mousa S: Diagnosis of pulmonary embolism by use of urinary TNF-alpha and its soluble TNF receptor I. Angiology 1999;50:703–706.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
